PDCD1

Revvity Expands Access to Base Editing Technology With Aim to Accelerate Discovery to Cure

Retrieved on: 
Tuesday, September 26, 2023
Research, Medical Devices, Genetics, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, TRAC, Drug development, Gene editing, PDCD1, CD58, Cancer, Messenger, RNA, Genomics, AstraZeneca, Cell, Cas9, Laboratory, APOBEC, Diagnosis, NYSE, DSM-IV codes, Pin, Vaccine, Pharmaceutical industry, CRISPR

Revvity , Inc., (NYSE: RVTY) today unveils its groundbreaking Pin-point™ base editing platform reagents, providing researchers with unparalleled access to implement the advanced gene editing technique in their preclinical laboratories.

Key Points: 
  • Revvity , Inc., (NYSE: RVTY) today unveils its groundbreaking Pin-point™ base editing platform reagents, providing researchers with unparalleled access to implement the advanced gene editing technique in their preclinical laboratories.
  • The Pin-point platform is one of the few established base editing technologies currently being employed in clinical settings, positioning it as both a discovery and therapeutic tool.
  • The introduction of Pin-point base editing reagents signifies a momentous stride toward democratizing access to base editing.
  • However, with the newly launched reagents, scientists now have the ability to fully evaluate the Pin-point base editing platform in-house.

KromaTiD Launches directional Genomic Hybridization (dGH) in-Site™ DNA Probes, Expanding Access for Cell and Gene Therapy Research Programs

Retrieved on: 
Thursday, July 20, 2023
FISH, CD19, Telomere, QC, NGS, PDCD1, Single-cell analysis, CIITA, Research, ISH, Genome, CAR, Comparative genomic hybridization, Centromere, DdPCR, DGH, IND, Antibiotics, Microscope

KromaTiD dGH™ products and services are widely used to assess genomic structural variation and gene-editing outcomes that cannot be identified using next generation sequencing (NGS) or fluorescence in-situ hybridization (FISH).

Key Points: 
  • KromaTiD dGH™ products and services are widely used to assess genomic structural variation and gene-editing outcomes that cannot be identified using next generation sequencing (NGS) or fluorescence in-situ hybridization (FISH).
  • Making these dGH in-Site™ probes commercially available enables research institutes and core labs as well as biopharma and pharmaceutical companies to economically design and execute dGH in-Site™ assays in-house.
  • "The key difference between dGH™ and other in-situ hybridization (ISH) methods is the outcome: dGH ™provides a much deeper data set than any other genomic ISH technique," explains KromaTiD Chief Technology Officer, Christopher Tompkins.
  • This is extremely valuable at all stages of a cell and gene therapy program, from research to preclinical to IND filing to QC testing of drug product."

CARIBOU DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Caribou Biosciences, Inc. and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, April 8, 2023
P.C, Rachel Haurwitz, IPO, Reindeer, Class, Telephone, PDCD1, Person, Register, Prospectus, District court, Patient, Form, CR, Court, News, Registration statement, Security (finance), Vaccine, Cryptocurrency, Defendant

Investors have until April 11, 2023 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until April 11, 2023 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • Additionally, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and prospects.
  • On June 10, 2022, Caribou issued a press release reporting “[p]ositive” data from the ANTLER Phase 1 clinical trial.
  • As of the time this Complaint was filed, Caribou common stock continues to trade below the $16.00 per share Offering price, damaging investors.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against PLDT, Global Payments, Caribou, and Inspirato and Encourages Investors to Contact the Firm

Retrieved on: 
Monday, April 3, 2023
P.C, Rachel Haurwitz, IPO, ISPO, Reindeer, Bank statement, Class, Global Payments, PDCD1, PLDT, SPO, Register, Prospectus, GPN, Consumer Financial Protection Bureau, Patient, Risk, Complaint, Form, CR, Active networking, Consumer, ASU, Inspirato, News, NYSE, Registration statement, Holding company, Audit, Cryptocurrency, Vaccine, Security (finance), Pharmaceutical industry, Defendant

Based on these facts, the Company’s public statements were false and materially misleading throughout the class period.

Key Points: 
  • Based on these facts, the Company’s public statements were false and materially misleading throughout the class period.
  • For more information on the PLDT class action go to: https://bespc.com/cases/PHI
    Global Payments is a Georgia company headquartered in Atlanta, Georgia.
  • Global Payments is a leading payments technology company that delivers innovative software and services to merchants and financial institutions worldwide.
  • Throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operational, and compliance policies.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Caribou, Inspirato, Kornit, and Alico and Encourages Investors to Contact the Firm

Retrieved on: 
Tuesday, March 28, 2023
Audit committee, IPO, ISPO, Citrus, Land management, Class, Amazon (company), Register, DTG, Patient, News, P.C, Maintenance, Rachel Haurwitz, Reindeer, DTF, SPO, ASU, Fanaticism, Registration statement, ALCO, Workflow, Disclosure, Annual report, Complaint, KRNT, Form, CR, Inspirato, Textile, Bank statement, Audit, PDCD1, Clothing, Prospectus, State, Holding company, Vaccine, Security (finance), Cryptocurrency, Online shopping, Video game, Kornit Digital, Defendant

Additionally, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and prospects.

Key Points: 
  • Additionally, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and prospects.
  • On June 10, 2022, Caribou issued a press release reporting “[p]ositive” data from the ANTLER Phase 1 clinical trial.
  • As of the time this Complaint was filed, Caribou common stock continues to trade below the $16.00 per share Offering price, damaging investors.
  • For more information on the Caribou class action go to: https://bespc.com/cases/CRBU
    According to the Complaint, the Company made false and misleading statements to the market.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Atlassian, PLDT, Global Payments, and Caribou and Encourages Investors to Contact the Firm

Retrieved on: 
Thursday, March 23, 2023
Cloud, P.C, IPO, Reindeer, Class, Global Payments, PDCD1, Confluence, Carnival Corporation & plc, PLDT, SPO, Register, Prospectus, GPN, Consumer Financial Protection Bureau, Patient, Risk, Complaint, Form, Jira (software), CR, Exhibit, Active networking, Consumer, Letter, News, NYSE, Registration statement, Holding company, Security (finance), Audit, Cryptocurrency, Vaccine, Pharmaceutical industry, Atlassian, Defendant

In 2020, Atlassian began to transition its clients to the cloud, which has accounted for a rapidly growing portion of the Company’s revenues.

Key Points: 
  • In 2020, Atlassian began to transition its clients to the cloud, which has accounted for a rapidly growing portion of the Company’s revenues.
  • As a result, Defendants’ positive statements about the Company’s business, operations, and prospects during the Class Period were materially false and /or misleading.
  • For more information on the PLDT class action go to: https://bespc.com/cases/PHI
    Global Payments is a Georgia company headquartered in Atlanta, Georgia.
  • As of the time this Complaint was filed, Caribou common stock continues to trade below the $16.00 per share Offering price, damaging investors.

CARIBOU BIOSCIENCES, INC. (NASDAQ: CRBU) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Caribou Biosciences, Inc. (NASDAQ: CRBU)

Retrieved on: 
Monday, March 20, 2023
Rachel Haurwitz, IPO, Class, PDCD1, Register, Prospectus, District court, Investment, Patient, Advertising, Form, CR, Court, Action Replay, News, Registration statement, Tobacco, Security (finance), Vaccine, Cryptocurrency, Reindeer, Defendant

NEW YORK, March 20, 2023 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or otherwise acquired: (a) Caribou Biosciences, Inc. (“Caribou” or the “Company”) (NASDAQ: CRBU) common stock pursuant and/or traceable to the Offering Documents issued in connection with the Company’s initial public offering conducted on or about July 23, 2021 (the “IPO” or “Offering”); and/or (b) Caribou securities between July 23, 2021 and December 9, 2022, both dates inclusive (the “Class Period”). The lawsuit was filed in the United States District Court for the Northern District of California and alleges violations of the Securities Act of 1933 and the Securities Exchange Act of 1934.

Key Points: 
  • Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or [email protected] to discuss your rights.
  • If you wish to serve as lead plaintiff, you must move the Court no later than April 11, 2023.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Caribou, Inspirato, Kornit, and Alico and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, March 18, 2023
Audit committee, IPO, ISPO, Citrus, Land management, Class, Amazon (company), Register, DTG, Patient, News, P.C, Maintenance, Rachel Haurwitz, Reindeer, DTF, SPO, ASU, Fanaticism, Registration statement, ALCO, Workflow, Disclosure, Annual report, Complaint, KRNT, Form, CR, Inspirato, Textile, Bank statement, Audit, PDCD1, Clothing, Prospectus, State, Cryptocurrency, Vaccine, Security (finance), Holding company, Online shopping, Video game, Kornit Digital, Defendant

Additionally, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and prospects.

Key Points: 
  • Additionally, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and prospects.
  • On June 10, 2022, Caribou issued a press release reporting “[p]ositive” data from the ANTLER Phase 1 clinical trial.
  • As of the time this Complaint was filed, Caribou common stock continues to trade below the $16.00 per share Offering price, damaging investors.
  • For more information on the Caribou class action go to: https://bespc.com/cases/CRBU
    According to the Complaint, the Company made false and misleading statements to the market.

CARIBOU BIOSCIENCES, INC. (NASDAQ: CRBU) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Caribou Biosciences, Inc. (NASDAQ: CRBU)

Retrieved on: 
Monday, March 13, 2023
Court, IPO, Form, Rachel Haurwitz, District court, Investment, Prospectus, Action Replay, News, Patient, CR, PDCD1, Register, Advertising, Class, Registration statement, Tobacco, Security (finance), Vaccine, Cryptocurrency, Reindeer, Defendant

NEW YORK, March 13, 2023 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or otherwise acquired: (a) Caribou Biosciences, Inc. (“Caribou” or the “Company”) (NASDAQ: CRBU) common stock pursuant and/or traceable to the Offering Documents issued in connection with the Company’s initial public offering conducted on or about July 23, 2021 (the “IPO” or “Offering”); and/or (b) Caribou securities between July 23, 2021 and December 9, 2022, both dates inclusive (the “Class Period”). The lawsuit was filed in the United States District Court for the Northern District of California and alleges violations of the Securities Act of 1933 and the Securities Exchange Act of 1934.

Key Points: 
  • Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or [email protected] to discuss your rights.
  • If you wish to serve as lead plaintiff, you must move the Court no later than April 11, 2023.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Global Payments, Caribou, Inspirato, and Kornit and Encourages Investors to Contact the Firm

Retrieved on: 
Monday, March 13, 2023
Active networking, Risk, SPO, Class, Consumer, Global Payments, ASU, Rachel Haurwitz, GPN, News, KRNT, Patient, Bank statement, Inspirato, Amazon (company), IPO, P.C, Form, NYSE, Reindeer, Fanaticism, Clothing, DTG, Register, DTF, Consumer Financial Protection Bureau, Complaint, Maintenance, ISPO, Prospectus, Textile, CR, Workflow, PDCD1, Registration statement, Holding company, Cryptocurrency, Online shopping, Vaccine, Security (finance), Audit, Video game, Kornit Digital, Defendant

Global Payments is a leading payments technology company that delivers innovative software and services to merchants and financial institutions worldwide.

Key Points: 
  • Global Payments is a leading payments technology company that delivers innovative software and services to merchants and financial institutions worldwide.
  • Throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operational, and compliance policies.
  • On this news, the price of Global Payments’ stock fell precipitously and closed at $113.67 on October 18, 2022.
  • As a result of these disclosures, the price of Kornit ordinary shares declined by $18.78 per share, or 33.3%.